News Release

Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: This randomized clinical trial found that in patients with advanced heart failure treated with a fully magnetically levitated left ventricular assist device, avoidance of aspirin as part of an antithrombotic regimen, which includes a vitamin K antagonist, is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events. 

Authors: Mandeep R. Mehra, M.D., M.Sc., of Brigham and Women’s Hospital and Harvard Medical School in Boston, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.23204)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the American Heart Association’s Scientific Sessions 2023.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.23204?guestAccessKey=36be1cb8-a086-4f1e-ac7e-1ff334f94ccc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111123


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.